Recombinant Human Myostatin Propeptide (M1107-GRP)

Myostatin propeptide (MRPO) has a very high binding affinity to myostatin and is a natural inhibitor of myostatin. MPRO is considered an attractive strategy for the treatment of muscle-wasting diseases such as muscular dystrophies.1 Disruption of myostatin function by its propeptide, shifts dietary fat utilization toward muscle tissues with minimal effects on adiposity, therefore, enhancing muscle growth by myostatin propeptide during the early developmental stage. It may also serve as an effective means for obesity prevention.2